known pregnancy (positive urine or serum pregnancy test) currently receiving an immunomodulatory agent for the treatment of covid-19 (including participation in clinical trials of such agents where treatment allocation is blinded or allocated on an open label basis). body mass index (bmi) ≥ 40 kg/m2or weight ≥ 130 kg anticipated transfer to another hospital, which is not a study site within 72 hours expected to die within 6 months of treatment due to underlying chronic disease limitations of care in place during current hospital admission -

known pregnancy (positive urine or serum pregnancy test) currently receiving an immunomodulatory agent for the treatment of covid-19 (including participation in clinical trials of such agents where treatment allocation is blinded or allocated on an open label basis). body mass index (bmi) ≥ 40 kg/m2or weight ≥ 130 kg anticipated transfer to another hospital, which is not a study site within 72 hours expected to die within 6 months of treatment due to underlying chronic disease limitations of care in place during current hospital admission -

1. known pregnancy (positive urine or serum pregnancy test) 2. currently receiving an immunomodulatory agent for the treatment of covid-19 (including participation in clinical trials of such agents where treatment allocation is blinded or allocated on an open label basis). 3. body mass index (bmi) ≥ 40 kg/m2or weight ≥ 130 kg 4. anticipated transfer to another hospital, which is not a study site within 72 hours 5. expected to die within 6 months of treatment due to underlying chronic disease 6. limitations of care in place during current hospital admission -

1. known pregnancy (positive urine or serum pregnancy test) 2. currently receiving an immunomodulatory agent for the treatment of covid-19 (including participation in clinical trials of such agents where treatment allocation is blinded or allocated on an open label basis). 3. body mass index (bmi) ≥ 40 kg/m2or weight ≥ 130 kg 4. anticipated transfer to another hospital, which is not a study site within 72 hours 5. expected to die within 6 months of treatment due to underlying chronic disease 6. limitations of care in place during current hospital admission -

1. known pregnancy (positive urine or serum pregnancy test) 2. currently receiving an immunomodulatory agent for the treatment of covid-19 (including participation in clinical trials of such agents where treatment allocation is blinded or allocated on an open label basis). 3. weight > 95 kg 4. anticipated transfer to another hospital, which is not a study site within 72 hours 5. expected to die within 6 months of treatment due to underlying chronic disease 6. limitations of care in place during current hospital admission -

1. known pregnancy (positive urine or serum pregnancy test) 2. currently receiving an immunomodulatory agent for the treatment of covid-19 (including participation in clinical trials of such agents where treatment allocation is blinded or allocated on an open label basis). 3. weight > 95 kg 4. anticipated transfer to another hospital, which is not a study site within 72 hours 5. expected to die within 6 months of treatment due to underlying chronic disease 6. limitations of care in place during current hospital admission -